IDORSIA PHARMACEUTICALS LTD.

Class 005: Pharmaceutical preparations for the treatment of cardiovascular and pulmonary diseases, inflammatory diseases, cancer, auto-immune disorders, neurodegenerative diseases, neurological disorders, anxiety, addictions including addictive eating disorders, neurodegenerative disorders including Alzheimer's disease, diseases of the central nervous system, glycolipid storage disorders, Fabry disease and symptoms and sequelae of Fabry disease, and allergic diseases; Pharmaceutical preparations for the treatment of hypertension, diabetes, and kidney diseases, including chronic kidney disease, diabetic kidney disease, and kidney diseases associated with glycolipid storage disorders and Fabry disease

Class 005: Pharmaceutical preparations for human use for the prevention and treatment of cardiovascular, circulatory and pulmonary diseases and disorders, hypertension, chronic and diabetic kidney diseases and disorders, nephrotic syndrome diseases and disorders, nephritic syndrome diseases and disorders, diabetic nephropathy, cerebrovascular diseases and disorders, glaucoma

Class 005: Pharmaceutical preparations for Pharmaceutical preparations for cardiovascular, pulmonary, inflammatory indications, for the treatment of pathological incidents of the central nervous system, in particular subarachnoid hemorrhage and sequelae thereof; pharmaceutical products for the treatment of cancer

Class 005: Pharmaceutical preparations for human use for the treatment of Fabry disease and symptoms and sequelae of Fabry disease, for the treatment of glycolipid storage disorders, and for the treatment of cancer

Pharmaceutical and veterinary products, namely, vaccines, and pharmaceutical and veterinary preparations for the prevention and treatment of infections; sanitary preparations for medical purposes; disinfectants

Pharmaceutical preparations for prevention or treatment of cardiovascular diseases, hypertension, vasospasms associated with aneurysmal subarachnoid hemorrhage, kidney diseases, pulmonary diseases, fibrotic diseases, cystic fibrosis, inflammatory diseases, allergic diseases, autoimmune diseases and disorders, neurodegenerative diseases, neurological disorders, diseases and disorders of the central nervous system, dementia, insomnia, anxiety disorders, drug addiction, eating disorders, epilepsy, metabolic disorders, diabetes, glycolipid storage disorders, Fabry disease and symptoms and sequelae of Fabry disease, infectious diseases and cancer

Human pharmaceutical preparations for the prevention and treatment of viral diseases, autoimmune and inflammatory diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, digital ulcers, and cerebrovascular diseases; vaccines; anxiolytics; pharmaceutical anti-allergic preparations and substances; anti-infectives; Medical information services related to pharmaceutical preparations for the prevention and treatment of viral diseases, autoimmune and inflammatory diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, digital ulcers, and cerebrovascular diseases, vaccines, anxiolytics, pharmaceutical anti-allergic preparations and substances, and anti-infectives

Pharmaceutical preparations intended for the prevention or treatment of cardiovascular diseases, hypertension, cerebral haemorrhages and sequela thereof, kidney diseases, pulmonary diseases, fibrotic diseases, cystic fibrosis, inflammatory diseases, allergy diseases, autoimmune diseases and disorders, neurodegenerative diseases and disorders, neurological diseases and disorders, central nervous system diseases and disorders, dementia, insomnia, anxiety disorders, addictions, eating disorders, epilepsy, metabolic disorders, diabetes, glycolipid storage diseases, Fabry disease and Fabry disease symptoms and sequela, infectious diseases and cancer

Providing educational information in the field of sleep disorders for patients and health care personnel

"SLEEP"

Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, digital ulcers, and cerebrovascular diseases; vaccines; anxiolytics; anti-allergics; anti-infectives

Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, digital ulcers, and cerebrovascular diseases; vaccines; anxiolytics; pharmaceutical anti-allergic preparations and substances; anti-infectives

Pharmaceutical preparations for human use for the treatment of Fabry disease and symptoms and sequelae of Fabry disease, and for the treatment of glycolipid storage disorders

Pharmaceutical preparations for human use for the treatment of Fabry disease and symptoms and sequelae of Fabry disease, and for the treatment of glycolipid storage disorders

Downloadable electronic publications in the nature of newsletters and test results in the nature of test results documents and test result forms the field of medical tests which are used for identifying symptoms of insomnia in patients and the effects of insomnia disorders on patients or symptoms of mental disorders associated with insomnia in patients and the effects of mental disorders associated with insomnia disorders on patients and in the field of collection of medical data which are used for identifying symptoms of insomnia in patients and the effects of insomnia disorders on patients or symptoms of mental disorders associated with insomnia in patients and the effects of mental disorders associated with insomnia disorders on patients | Printed matter in the nature of newsletters and brochures in the field of medical tests which are used for identifying symptoms of insomnia in patients and the effects of insomnia disorders on patients or symptoms of mental disorders associated with insomnia in patients and the effects of mental disorders associated with insomnia disorders on patients and in the field of collection of medical data which are used for identifying symptoms of insomnia in patients and the effects of insomnia disorders on patients or symptoms of mental disorders associated with insomnia in patients and the effects of mental disorders associated with insomnia disorders on patients | Multimedia publication of printed matter in the nature of newsletters, brochures, and test results in the nature of test results documents and test result forms in the field of medical tests which are used for identifying symptoms of insomnia in patients and the effects of insomnia disorders on patients or symptoms of mental disorders associated with insomnia in patients and the effects of mental disorders associated with insomnia disorders on patients and in the field of collection of medical data which are used for identifying symptoms of insomnia in patients and the effects of insomnia disorders on patients or symptoms of mental disorders associated with insomnia in patients and the effects of mental disorders associated with insomnia disorders on patients; multimedia publication of printed matter in the nature of books, magazines and journals in the field of tests which are used for identifying symptoms of insomnia in patients and the effects of insomnia disorders on patients or symptoms of mental disorders associated with insomnia in patients and the effects of mental disorders associated with insomnia disorders on patients and in the field of collection of medical data which are used for identifying symptoms of insomnia in patients and the effects of insomnia disorders on patients or symptoms of mental disorders associated with insomnia in patients and the effects of mental disorders associated with insomnia disorders on patients | Scientific research and development, namely pharmaceutical testing and medical testing services not for diagnostic or treatment purposes and development of pharmaceutical and medical tests, all which are used for identifying symptoms of insomnia in patients and the effects of insomnia disorders on patients or symptoms of mental disorders associated with insomnia in patients and the effects of mental disorders associated with insomnia disorders on patients; scientific research, namely analysis of objective data on patients that was acquired by means of diagnostic tests in the context of drug administration, analysis of subjective data on patients that was acquired by means of patient questioning, analysis of such data with the aim of optimizing drug treatments and drug administration

Pharmaceutical preparations for humans for the prevention and treatment of cardiovascular diseases, hypertension, brain haemorrhage and sequelae thereof, kidney diseases, pulmonary diseases, fibrotic diseases, cystic fibrosis, inflammatory diseases, allergic diseases, auto-immune diseases and disorders, neurodegenerative diseases and disorders, neurological diseases and disorders, diseases and disorders of the central nervous system, dementia, sleep disorders, anxiety disorders, addictions, eating disorders, epilepsy, metabolic disorders, diabetes, glycolipid storage disorders, Fabry disease and symptoms and sequelae of Fabry disease, infectious diseases, and cancer

Pharmaceutical preparations for treatment of cerebral hemorrhages and their sequelae

Pharmaceutical preparations for the prevention or treatment of neurological disorders, diseases and disorders of the central nervous system, sleep disorders

Pharmaceutical preparations for humans for the prevention and treatment of cardiovascular diseases, hypertension, vasospasm associated with aneurysmal subarachnoid hemorrhage, kidney diseases, pulmonary diseases, fibrotic diseases, cystic fibrosis, inflammatory diseases, allergic diseases, auto-immune diseases and disorders, neurodegenerative diseases, neurological disorders, diseases and disorders of the central nervous system, dementia, sleep disorders, anxiety disorders, addictions, eating disorders, epilepsy, metabolic disorders, diabetes, glycolipid storage disorders, Fabry disease and symptoms and sequelae of Fabry disease, infectious diseases, and cancer

Pharmaceutical preparations for the prevention or treatment of cardiovascular diseases, hypertension, brain haemorrhage and sequelae thereof, kidney diseases, pulmonary diseases, fibrotic diseases, cystic fibrosis, inflammatory diseases, allergic diseases, auto-immune diseases and disorders, neurodegenerative diseases and disorders, neurological diseases and disorders, diseases and disorders of the central nervous system, dementia, sleep disorders, anxiety disorders, addictions, eating disorders, epilepsy, metabolic disorders, diabetes, glycolipid storage disorders, Fabry disease and symptoms and sequelae of Fabry disease, infectious diseases, and cancer

Pharmaceutical preparations for humans for the prevention and treatment of cardiovascular diseases, hypertension, brain haemorrhage and sequelae thereof, kidney diseases, pulmonary diseases, fibrotic diseases, cystic fibrosis, inflammatory diseases, allergic diseases, auto-immune diseases and disorders, neurodegenerative diseases and disorders, neurological diseases and disorders, diseases and disorders of the central nervous system, dementia, sleep disorders, anxiety disorders, addictions, eating disorders, epilepsy, metabolic disorders, diabetes, glycolipid storage disorders, Fabry disease and symptoms and sequelae of Fabry disease, infectious diseases, and cancer

Pharmaceutical preparations for the treatment of cardiovascular and pulmonary diseases, inflammatory diseases, cancer, auto-immune disorders, neurodegenerative diseases, neurological disorders, anxiety, addictions including addictive eating disorders, and neurodegenerative disorders including Alzheimer's disease, diseases of the central nervous system, glycolipid storage disorders, Fabry disease and symptoms and sequelae of Fabry disease, and allergic diseases

Pharmaceutical products for human use for the treatment of Fabry disease and symptoms and sequelae of Fabry disease, excluding products used in cell therapy or gene therapy or for treatment of blood diseases

Pharmaceutical preparations for cardiovascular, pulmonary, inflammatory indications, for the treatment of pathological incidents of the central nervous system, in particular subarachnoid hemorrhage and sequelae thereof, as well as for the treatment of cancer

Pharmaceutical, medical [ and veterinary ] preparations for the treatment of cardiovascular and pulmonary diseases, inflammatory diseases, [ cancer, auto-immune disorders, ] neurodegenerative diseases, diseases of the central nervous system [ , glycolipid storage disorders, allergic diseases; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; food supplements for humans and animals; plasters, namely, medical plasters, and materials for dressings, namely, adhesive plasters for medical purposes; disinfectants; fungicides ]; Medical services [ ; veterinary services; hygienic and beauty care for human beings or animals ]; Scientific and technological services, namely, research and design services in the field of pharmaceuticals; industrial analysis and research services in the pharmaceutical industry [ ; design and development of computer hardware and software ]

Pharmaceutical, medical [ and veterinary ] preparations for the treatment of cardiovascular and pulmonary diseases, inflammatory diseases, [ cancer, ] auto-immune disorders, neurodegenerative diseases, diseases of the central nervous system [ , glycolipid storage disorders, and allergic diseases; sanitary preparations for medical purposes; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; food supplements for humans and animals; plasters, namely, medical plasters, and materials for dressings, namely, adhesive plasters for medical purposes; disinfectants; fungicides ]; Medical services [ ; veterinary services; hygienic and beauty care for human beings or animals ]; Scientific and technological services, namely, research and design services in the field of pharmaceuticals; industrial analysis and research services in the pharmaceutical industry [ ; design and development of computer hardware and software ]

Pharmaceutical preparations for cardiovascular, pulmonary, inflammatory indications as well as for the treatment of cancer

Pharmaceutical preparations for cardiovascular, pulmonary, inflammatory indications as well as for the treatment of cancer

Pharmaceutical preparations for the prevention or treatment of cardiovascular diseases, hypertension, vasospasm associated with aneurysmal subarachnoid hemorrhage, kidney diseases, pulmonary diseases, fibrotic diseases, cystic fibrosis, inflammatory diseases, allergic diseases, auto-immune diseases and disorders, neurodegenerative diseases, neurological disorders, diseases and disorders of the central nervous system, dementia, sleep disorders, anxiety disorders, addictions, eating disorders, epilepsy, metabolic disorders, diabetes, glycolipid storage disorders, Fabry disease and symptoms and sequelae of Fabry disease, infectious diseases, and cancer